Patients with asthma and allergic bronchopulmonary aspergillosis experienced improvements with dupilumab, according to data presented at the American Thoracic Society International Conference.Quality ...

Table 1. Clinical staging of allergic bronchopulmonary aspergillosis in patients with asthma. Stage Definition Features; 0: Asymptomatic: Never diagnosed to have ABPA in the past, presentation ...

BOSTON — Symptoms improved with mepolizumab after treatment with omalizumab failed for a patient with asthma who developed allergic bronchopulmonary aspergillosis, according to a poster ...

N ot just pneumonia or bronchitis but even asthma cases are rising in monsoon in all age Group. Dampness in the house, a rise in humidity, viruses, fungi, bacteria, molds, and dust mites can spike ...

One study calculated that 2.5% of adults who have asthma also have ABPA, ... Of these 4.8 million people who have ABPA, an estimated 400,000 also have chronic pulmonary aspergillosis (CPA).

LEXINGTON, Mass., May 2, 2023 /PRNewswire/ -- Pulmatrix, Inc. (PULM) (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary ...

LEXINGTON, Mass., Feb. 6, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using ...

Future Microbiol. 2014;9(10):1195-1208. 0 Asymptomatic Never diagnosed to have ABPA in the past, presentation with controlled asthma (according to GINA guidelines) and meeting the diagnostic ...

One study calculated that 2.5% of adults who have asthma also have ABPA, ... Of these 4.8 million people who have ABPA, an estimated 400,000 also have chronic pulmonary aspergillosis (CPA).

LEXINGTON, Mass., Feb. 6, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using ...

LEXINGTON, Mass., Feb. 6, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using ...

LEXINGTON, Mass., Feb. 6, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using ...